vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and SIMMONS FIRST NATIONAL CORP (SFNC). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $197.3M, roughly 1.3× SIMMONS FIRST NATIONAL CORP). On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 19.6%). SIMMONS FIRST NATIONAL CORP produced more free cash flow last quarter ($411.4M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 0.6%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Simmons Bank is a bank with operations in Arkansas, Kansas, Missouri, Oklahoma, Tennessee, and Texas. It is the primary subsidiary of Simmons First National Corporation, a bank holding company.
ANIP vs SFNC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $197.3M |
| Net Profit | $27.5M | — |
| Gross Margin | — | — |
| Operating Margin | 14.1% | — |
| Net Margin | 11.1% | — |
| Revenue YoY | 29.6% | 19.6% |
| Net Profit YoY | 367.5% | — |
| EPS (diluted) | $1.14 | $0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $197.3M | ||
| Q3 25 | $227.8M | $186.7M | ||
| Q2 25 | $211.4M | $214.2M | ||
| Q1 25 | $197.1M | $209.6M | ||
| Q4 24 | $190.6M | $208.5M | ||
| Q3 24 | $148.3M | $174.8M | ||
| Q2 24 | $138.0M | $197.2M | ||
| Q1 24 | $137.4M | $195.1M |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $-562.8M | ||
| Q2 25 | $8.5M | $54.8M | ||
| Q1 25 | $15.7M | $32.4M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $24.7M | ||
| Q2 24 | $-2.3M | $40.8M | ||
| Q1 24 | $18.2M | $38.9M |
| Q4 25 | 14.1% | — | ||
| Q3 25 | 15.9% | — | ||
| Q2 25 | 6.6% | — | ||
| Q1 25 | 13.3% | — | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -13.8% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | 14.8% | — |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | -301.5% | ||
| Q2 25 | 4.0% | 25.6% | ||
| Q1 25 | 8.0% | 15.5% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | 14.1% | ||
| Q2 24 | -1.7% | 20.7% | ||
| Q1 24 | 13.2% | 19.9% |
| Q4 25 | $1.14 | $0.36 | ||
| Q3 25 | $1.13 | $-4.00 | ||
| Q2 25 | $0.36 | $0.43 | ||
| Q1 25 | $0.69 | $0.26 | ||
| Q4 24 | $-0.45 | $0.38 | ||
| Q3 24 | $-1.27 | $0.20 | ||
| Q2 24 | $-0.14 | $0.32 | ||
| Q1 24 | $0.82 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | — |
| Total DebtLower is stronger | — | $620.0M |
| Stockholders' EquityBook value | $540.7M | $3.4B |
| Total Assets | $1.4B | $24.5B |
| Debt / EquityLower = less leverage | — | 0.18× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — | ||
| Q1 24 | $228.6M | — |
| Q4 25 | — | $620.0M | ||
| Q3 25 | — | $667.8M | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $540.7M | $3.4B | ||
| Q3 25 | $505.8M | $3.4B | ||
| Q2 25 | $436.8M | $3.5B | ||
| Q1 25 | $418.6M | $3.5B | ||
| Q4 24 | $403.7M | $3.5B | ||
| Q3 24 | $405.9M | $3.5B | ||
| Q2 24 | $455.8M | $3.5B | ||
| Q1 24 | $452.0M | $3.4B |
| Q4 25 | $1.4B | $24.5B | ||
| Q3 25 | $1.4B | $24.2B | ||
| Q2 25 | $1.3B | $26.7B | ||
| Q1 25 | $1.3B | $26.8B | ||
| Q4 24 | $1.3B | $26.9B | ||
| Q3 24 | $1.3B | $27.3B | ||
| Q2 24 | $920.8M | $27.4B | ||
| Q1 24 | $914.5M | $27.4B |
| Q4 25 | — | 0.18× | ||
| Q3 25 | — | 0.20× | ||
| Q2 25 | — | 0.28× | ||
| Q1 25 | — | 0.35× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.50× | ||
| Q1 24 | — | 0.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $449.5M |
| Free Cash FlowOCF − Capex | $29.1M | $411.4M |
| FCF MarginFCF / Revenue | 11.8% | 208.5% |
| Capex IntensityCapex / Revenue | 0.5% | 19.3% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $717.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $449.5M | ||
| Q3 25 | $44.1M | $223.4M | ||
| Q2 25 | $75.8M | $77.6M | ||
| Q1 25 | $35.0M | $32.8M | ||
| Q4 24 | $15.9M | $425.9M | ||
| Q3 24 | $12.5M | $199.4M | ||
| Q2 24 | $17.4M | $86.1M | ||
| Q1 24 | $18.3M | $57.6M |
| Q4 25 | $29.1M | $411.4M | ||
| Q3 25 | $38.0M | $216.7M | ||
| Q2 25 | $71.8M | $66.3M | ||
| Q1 25 | $32.5M | $22.6M | ||
| Q4 24 | $13.5M | $380.4M | ||
| Q3 24 | $7.7M | $187.7M | ||
| Q2 24 | $13.0M | $72.7M | ||
| Q1 24 | $13.7M | $47.7M |
| Q4 25 | 11.8% | 208.5% | ||
| Q3 25 | 16.7% | 116.1% | ||
| Q2 25 | 34.0% | 31.0% | ||
| Q1 25 | 16.5% | 10.8% | ||
| Q4 24 | 7.1% | 182.5% | ||
| Q3 24 | 5.2% | 107.4% | ||
| Q2 24 | 9.4% | 36.9% | ||
| Q1 24 | 10.0% | 24.5% |
| Q4 25 | 0.5% | 19.3% | ||
| Q3 25 | 2.7% | 3.6% | ||
| Q2 25 | 1.9% | 5.3% | ||
| Q1 25 | 1.3% | 4.8% | ||
| Q4 24 | 1.3% | 21.8% | ||
| Q3 24 | 3.2% | 6.7% | ||
| Q2 24 | 3.2% | 6.8% | ||
| Q1 24 | 3.3% | 5.0% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | 1.42× | ||
| Q1 25 | 2.23× | 1.01× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 8.06× | ||
| Q2 24 | — | 2.11× | ||
| Q1 24 | 1.00× | 1.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
SFNC
Segment breakdown not available.
